Fig. 9 | Scientific Reports

Fig. 9

From: ASCL2 contributes to clinical assessments of breast cancer and mediates tumor progression via the interaction with CLDN3

Fig. 9

The oncogenic abilities of ASCL2 in xenograft tumors in mice. (A) Silencing ASCL2 suppresses the growth of xenograft tumors in mice; (B) Differences in tumor weight between sh-vector and sh-ASCL2 groups; (C) Differences in tumor volumes between sh-vector and sh-ASCL2 groups; (D) The core module of genes that are highly related to ASCL2; (E) Expressive correlation between ASCL2 and CLDN3 (TCGA-BRCA cohort); (F) Overall survival differences between high- and low-CLDN3 expression groups (TCGA-BRCA cohort); **P < 0.01.

Back to article page